Similar articles

• A future for regulatory science in the European Union: the European Medicines Agency's strategy.

  Hines PA, Janssens R, Gonzalez-Quevedo R, Lambert AIOM, Humphreys AJ. Hines PA, et al. Nat Rev Drug Discov. 2020 May;19(5):293-294. doi: 10.1038/d41573-020-00032-0. Nat Rev Drug Discov. 2020. PMID: 32235873 No abstract available.
• EU directive on clinical trials penalizes small sponsors.

  Meldolesi A. Meldolesi A. Nat Biotechnol. 2003 Aug;21(8):838. doi: 10.1038/nbt0803-838. Nat Biotechnol. 2003. PMID: 12894186 No abstract available.
• FDA and EMEA pool scientific advice.

  Katsnelson A. Katsnelson A. Nat Biotechnol. 2004 Dec;22(12):1490-1. doi: 10.1038/nbt1204-1490. Nat Biotechnol. 2004. PMID: 15583642 No abstract available.
• [Experiences of the drug approval processes in the European Union].

  Pasanen M, Toivonen M. Pasanen M, et al. Duodecim. 2000;116(24):2817-22. Duodecim. 2000. PMID: 12077887 Review. Finnish. No abstract available.
• Drug regulation in the European Union.

  Griffin JP. Griffin JP. Adverse Drug React Toxicol Rev. 2000 Aug;19(3):179-206. Adverse Drug React Toxicol Rev. 2000. PMID: 11059359 Review. No abstract available.